Cookie Policy

This site uses cookies to store information on your computer. Some cookies on this site are needed because the site won’t work as expected without them. To learn more about cookies, please read our Cookie Policy. By closing this message or using the website, you agree to our use of cookies on this device in agreement with our Cookie Policy, unless you have turned them off.

Accept and Close

For UK Healthcare Professionals only

  • Request a Rep Visit
  • Prescribing Information
  • Keep in Touch With Sanofi
    • Cardiovascular Risk
      • Unmet Need
      • Dyslipidaemia guidelines interactive tool
      • NICE and SMC Guidance
    • Trial Data
      • Odyssey Outcomes - Trial Design
      • Odyssey Outcomes - Efficacy
      • Odyssey Outcomes - Outcomes in Diabetes Patients
      • Odyssey Outcomes - Safety
      • COMBO I Study
      • COMBO II Study
      • Long-term Study
      • FHI & FHII Studies
      • Alternative Study
      • Additional Studies
    • Patient Profiles
    • About Praluent
      • Indication
      • Specific characteristics
      • Mechanism of Action
      • Dosing
      • Administration
      • Homecare
      • MyPraluent Coach
    • Educational Resources
    • Patient Resources

    Healthcare Professional

    This website and its contents have been developed for UK healthcare professionals. In order to proceed into the website, please confirm that you are a UK healthcare professional by clicking the button below.

    Members of the Public

    If you are not a UK healthcare professional, please click the button below to be taken to the information site intended for the general public.

    I am a member of the public

    Praluent (alirocumab) Patients

    Information intended for UK residents prescribed with Praluent (or their carers), can be found at MyPraluent.co.uk

    Visit MyPraluent.co.uk

    Email a link to this page

    Your friend has shared this page about highs and lows

    send to another
    Your email has been sent

    Your email has been sent to:

    Important Safety Information

    Name and Presentation Praluent 75 mg solution for injection in pre-filled pen; Praluent 150 mg solution of injection in pre-filled pen; Praluent 75 mg solution of injection in pre-filled syringe; Praluent 150 mg solution of injection in pre-filled syringe. Each single-use pre-filled pen or syringe contains 75 mg or 150 mg alirocumab in 1 ml solution. Alirocumab is a human lgG1 monoclonal antibody produced in Chinese Hamster Ovary cells by recombinant DNA technology.

    Read Full Safety Information

    Important Safety Information

    Name and Presentation Praluent 75 mg solution for injection in pre-filled pen; Praluent 150 mg solution of injection in pre-filled pen; Praluent 75 mg solution of injection in pre-filled syringe; Praluent 150 mg solution of injection in pre-filled syringe. Each single-use pre-filled pen or syringe contains 75 mg or 150 mg alirocumab in 1 ml solution. Alirocumab is a human lgG1 monoclonal antibody produced in Chinese Hamster Ovary cells by recombinant DNA technology.

    Read Full Safety Information





    :

    Adverse events should be reported.

    Reporting forms and information can be found at yellowcard.mhra.gov.uk.

    Adverse events should also be reported to Sanofi on 0800 090 2314 or uk-drugsafety@sanofi.com.

    Your leaving the website

    This site is intended for U.S. Healthcare Professionals only.

    Do you wish to continue?

    You are leaving the Praluent.co.uk website

    By clicking on this link, you will be leaving this Sanofi hosted website, and, depending on the link, will be redirected either to another Sanofi website (for example, to view the Sanofi Privacy Policy) or to an independent third-party website.

    Sanofi has no control over the content or availability of third-party sites or resources that are linked to, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. The existence of a link between this website and any third party site or resource in no way implies that Sanofi in any way approves of the content of these sites or resources, or any use to which such content maybe put.

    Please ensure that you read the legal and privacy policy sections of any website to which you link.

     

    You are about to leave sanofi site for U.S.

    Sanofi US does not review the information contained on this website and/or database for content, accuracy or completeness. Use of and access to this information is subject to the terms, limitations and conditions set by the website and/or database producer.

    This site might not comply with the regulatory requirements of US

    You are about to move to an Unbranded site

    You are moving to an Unbranded site

    Sitemap
    Prescribing Information
    Keep in Touch With Sanofi
    Request a rep visit

    MAT-UK-2000326 (v5.0)
    August 2021

    This site is intended for UK Healthcare Professionals Only.

    Legal

    • Privacy Policy
    • Terms of Use
    • Cookie Policy

    Sanofi is hosting this website on behalf of Sanofi and Regeneron Pharmaceuticals, Inc.

    ©2021 Sanofi.
    All rights reserved